ΠŸΠΎΠΌΠΎΡ‰ΡŒ Π² ΡƒΡ‡Ρ‘Π±Π΅, ΠΎΡ‡Π΅Π½ΡŒ быстро...
Π Π°Π±ΠΎΡ‚Π°Π΅ΠΌ вмСстС Π΄ΠΎ ΠΏΠΎΠ±Π΅Π΄Ρ‹

Π›ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Π°. 
ЀармакотСрапия ΠΏΠΎΠ΄Π°Π³Ρ€Ρ‹

Π Π΅Ρ„Π΅Ρ€Π°Ρ‚ΠŸΠΎΠΌΠΎΡ‰ΡŒ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈΠ£Π·Π½Π°Ρ‚ΡŒ ΡΡ‚ΠΎΠΈΠΌΠΎΡΡ‚ΡŒΠΌΠΎΠ΅ΠΉ Ρ€Π°Π±ΠΎΡ‚Ρ‹

Ahbern M.J., Reid C., Gordon T.P. Does colchicine work? Results of the first controlled study in gout. Austr. N. Z. J. Med. 1987; 17: 301βˆ’4. Noda S., Hayashi K., Eto K. Oxalate crystallization in the kidney in the presence of hyperuricemia. Scanning Microsc. 1989; 3: 829βˆ’36. Singer J.Z., Wallace S.L. The allopurinol hypersensitivity syndrome. Unnecessary morbility and mortality. Arthr. Rheum… Π§ΠΈΡ‚Π°Ρ‚ΡŒ Π΅Ρ‰Ρ‘ >

Π›ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Π°. ЀармакотСрапия ΠΏΠΎΠ΄Π°Π³Ρ€Ρ‹ (Ρ€Π΅Ρ„Π΅Ρ€Π°Ρ‚, курсовая, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŒΠ½Π°Ρ)

1. Ahbern M.J., Reid C., Gordon T.P. Does colchicine work? Results of the first controlled study in gout. Austr. N. Z. J. Med. 1987; 17: 301−4.

2. Gillott T.J., Whallett A., Zaphiropoulos G. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity. Rheumatology 1999; 38: 85−6.

3. Groff G.D., Frank W.A., Raddatz D.A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Seminars in Arthr. Rheum. 1990; 19: 329−36.

4. Harris M.D., Siegel L.B., Alloway J.A. Gout and hyperuricemia. Am. Fam. Physician. 1999; 15: 925−34.

5. McDonald E., Marino C. Stopping progression to tophaceous gout. When and how to use urate-lowering therapy. Postgrad. Med. 1998; 104: 117−27.

6. Noda S., Hayashi K., Eto K. Oxalate crystallization in the kidney in the presence of hyperuricemia. Scanning Microsc. 1989; 3: 829−36.

7. Perez-Ruiz F., Alonso-Ruiz A., Calaabozo M. et al. Efficacy of allopurinol and benzbromarone for control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann. Rheum. Dis. 1998; 57: 545−9.

8. Perez-Ruiz F., Calaabozo M., Fernandez-Lopez J. et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J. Clin. Rheumatol. 1999; 5: 49−55.

9. Rozenberg S., Lang T., Laatar A., Koeger A.T. et al. Diversity of opinions on the management of gout in France: a survey of 750 rheumatologists. Rev. Rhum. 1996; 63: 255−61.

10. Singer J.Z., Wallace S.L. The allopurinol hypersensitivity syndrome. Unnecessary morbility and mortality. Arthr. Rheum. 1996; 29: 82−7.

11. Talbott J.H., Terplan K.L. The kidney in gout. Medicine 1960; 39: 405−68.

12. Wallace S.L., Singer J.Z. Review: systemic toxicity associated with the intravenous administration of colchicine — guidelines for use. J. Rheumatol. 1988; 15: 495−9.

13. Yamanaka H., Togashi R., Hakoda M. et al. Optimal range of serum urate concentrations ti minimize risk of gouty attacks during anti-hyperuremic treatment. Adv. Exp. Med. Biol. 1998; 431: 13−8.

14. Yu: T-F., Gutman A.B. Uric acid nephrolitiasis in gout: pridisposing factors. Ann. Intern. Med. 1967; 67: 1133−48.

15. Yu: T-F. Urolitiasis in hyperuricemia and gout. J. Urol. 1981; 126: 424−30.

ΠŸΠΎΠΊΠ°Π·Π°Ρ‚ΡŒ вСсь тСкст
Π—Π°ΠΏΠΎΠ»Π½ΠΈΡ‚ΡŒ Ρ„ΠΎΡ€ΠΌΡƒ Ρ‚Π΅ΠΊΡƒΡ‰Π΅ΠΉ Ρ€Π°Π±ΠΎΡ‚ΠΎΠΉ